CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory ...

Avacta Group, a developer of Affimer biotherapeutics and reagents, announced that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the ...

Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus Avacta Group plc (AIM: AVCT), the developer of Affimer® ...

Drug developer Avacta expects to launch a new laboratory test for the SARS-CoV-2 spike protein in the next few weeks. Did you know with a Digital subscription to Yorkshire Post, you can get access to ...

Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus Avacta Group plc (AIM: AVCT), the developer of Affimer ...

FDA actively reviewing Company’s EUA submission for its first of its kind “at-home” Blood Collection kit used with the Biomerica COVID-19 IgG ELISA Lab Test system IRVINE, Calif., Jan. 15, 2021 (GLOBE ...

Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus Avacta Group plc (AIM: AVCT), the developer of Affimer® ...